The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and only subcutaneously administered therapy for patients with epidermal growth ...

You may want to lose body fat but might not know exactly where fat is stored in your body. That’s when knowing the difference between subcutaneous fat and visceral fat can be handy. The main ...

Dose intensification of subcutaneous vedolizumab is beneficial for patients with IBD, particularly those with UC. Subcutaneous vedolizumab dose escalation is associated with clinical improvement in ...

In a merger between two subcutaneous drug delivery companies, Halozyme Therapeutics is paying $750 million in cash to acquire Elektrofi. Aside from the $750 million upfront payment, the deal also ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved a subcutaneous induction regimen of guselkumab for the treatment of adults with moderately ...

Description: #OctopusEffects, #aftereffects I shot a short video, then used Particular with the Physics of Fluids to make the cup dissolve into particles. Here is a detailed video on how to do it.

Merck (NYSE:MRK) said that the FDA has cleared Keytruda Qlex, a new subcutaneous version of its blockbuster cancer drug, offering a faster alternative to IV infusion, a company spokesperson confirmed ...

The FDA has approved Merck & Co.’s under-the-skin version of Keytruda, reducing treatment time burden for patients while granting the world’s bestselling drug potential blockbuster revenue protection.

Please provide your email address to receive an email when new articles are posted on . Patients who received subcutaneous amivantamab-vmjw every 4 weeks plus lazertinib had similar outcomes as those ...

The U.S. Food and Drug Administration has approved Leqembi Iqlik, a subcutaneous version of lecanemab, for weekly maintenance after the 18-month intravenous (IV) phase. Leqembi Iqlik is a subcutaneous ...

TORONTO -- An investigational subcutaneous autoinjector showed comparable efficacy and safety to the IV formulation of lecanemab (Leqembi) for maintenance treatment in early Alzheimer's disease, ...